Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

STAMFORD, Conn., Jan. 31, 2018 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the initiation of its first pivotal

Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

January 25, 2018 NEW YORK–(BUSINESS WIRE)– Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE®(plecanatide) 3 mg tablet for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This

Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Jan. 24, 2018 Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial rights for LUXTURNA™ (voretigene neparvovec-ryzl) Agreement leverages Novartis’ extensive ex-US ophthalmology capabilities and infrastructure to the benefit of patients